Iovance Biotherapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 361.89, 504.13, 756.91, 983.94, 1227.36 ], "ebit_estimate": [ -251.17, -146.99, 8.54, 102.2, 218.34 ], "ebitda_estimate": [ -237.17, -144.67, 4.08, null, null ], "net_income_estimate": [ -237.41, -132.99, 24.66, 107.93, 219.61 ], "per_share_eps_estimate": [ -0.56, -0.32, 0, 0.16, 0.36 ], "eps_nri_estimate": [ -0.54, -0.29, 0.04, 0.18, 0.36 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 1.5, 1.38, 1.45, null, null ], "pretax_income_estimate": [ -244.49, -140.78, 14.39, 108.17, 223.95 ], "operating_cash_flow_per_share_estimate": [ -0.25, -0.07, 0.14, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -19.37, -8.22, 6.24, null, null ], "gross_margin_estimate": [ 50.97, 64.15, 71.75, 74.6, 78.1 ], "operating_cash_flow_estimate": [ -104.63, -29.3, 58.59, null, null ], "pettm_estimate": [ 0, 0, 2115, 26.44, 11.65 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "41.87", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 41.87, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": -5.38, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 48.71, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 87.67, 95.77, 107.71, 108, 117.8, 124.27, 141 ], "ebit_estimate": [ -57.27, -52.82, -47.06, -39.45, -33.9, -28.2, -24.25 ], "ebitda_estimate": [ -54, -56.77, -53.41, null, null, null, null ], "net_income_estimate": [ -55.9, -53.49, -50.35, -38.75, -33.2, -27.5, -23.55 ], "per_share_eps_estimate": [ -0.13, -0.13, -0.12, -0.1, -0.09, -0.06, -0.04 ], "eps_nri_estimate": [ -0.13, -0.12, -0.11, -0.1, -0.09, -0.06, -0.04 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -58.26, -55.79, -52.73, -38.75, -33.2, -27.5, -23.55 ], "operating_cash_flow_per_share_estimate": [ -0.04, -0.04, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ -15.89, -14.34, -7.14, null, null, null, null ], "gross_margin_estimate": [ 52.03, 53.58, 55.05, 58, 60, 62, 64 ], "operating_cash_flow_estimate": [ -16.74, -16.74, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "41.87", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 41.87, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": -5.38, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 48.71, "future_operating_cash_flow_per_share_estimate_growth": null }